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Systemic Sclerosis (SSc) is a connective tissue disorder featuring vascular alterations and an immunological activation leading to a
progressive and widespread ﬁbrosis of several organs such as the skin, lung, gastrointestinal tract, heart, and kidney. Men with SSc
are at increased risk of developing erectile dysfunction (ED) because of the evolution of early microvascular tissutal damage into
corporeal ﬁbrosis. The entity of penile vascular damage in SSc patients has been demonstrated by using Duplex ultrasonography
and functional infra-red imaging and it is now clear that this is a true clinical entity invariably occurring irrespective of age and
disease duration and constituting the “sclerodermic penis”. Once-daily phosphodiesterase type-5 (PDE5) inhibitors improve both
sexual function and vascular measures of cavernous arteries by improving surrogate markers of endothelial dysfunction, that is,
plasma endothelin-1 and adrenomedullin levels, which may play a potential role in preventing progression of penile ﬁbrosis and
ED. Also, the beneﬁcial eﬀect of long-term PDE5i add-on therapy to SSc therapy in the treatment of Raynaud’s phenomenon is
described.
1.Introduction
Systemic Sclerosis (SSc) is a connective tissue disorder fea-
tured by vascular alterations and immunological activation
leading to progressive and widespread ﬁbrosis of several
organs such as skin, lung, gastrointestinal tract, heart, and
kidney [1, 2]. The typical hallmark of SSc is a microvascular
involvement, while macrovascular involvement is not well
documented in these patients, but the majority of authors
agree that its prevalence is similar to general population [3].
Vascular involvement in SSc has been believed to be limited
to digital arteries [4]. It is extremely rare that SSc patients
without vascular risk factors have macrovascular lesions
abovetheelboworknee.However,arelativelyhighincidence
of vascular involvement between the digits and the elbow
or knee has been described [5]. Early disease is mediated
through microvascular dysfunction secondary to a number
of factors including endothelial damage, overexpression of
speciﬁc adhesion molecules, and perivascular inﬂammatory
cell inﬁltration [6]. These changes make endothelium unable
to carry out its functions in the regulation of vascular
tone, coagulation, adhesions and migration of blood cells,
transportation of nutrients, achieved through production of
a complex array of molecules including vasodilators (e.g.,
nitric oxide: NO), vasoconstrictors (e.g., endothelin-1: ET-
1), and cell adhesion molecules (e.g., selectins and integrins)
[7]. The endothelial dysfunction can explain some major
clinical symptoms of SSc such as Raynaud’s phenomenon
(RP), ﬁngertip ulcers and gangrene, pulmonary arterial
hypertension and erectile dysfunction (ED) (Figure 1). Irre-
spective of the classiﬁcation of the disease, SSc is typically
associated with RP that is characterized by microvascular
damage, high plasma adrenomedullin and ET-1 levels,
reduced production of NO [8–11].
Similarly, at the penile level, there occurs a consis-
tent vascular damage that almost invariably determines,2 International Journal of Rheumatology
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as a consequence of both endothelium damage [12–16]
and increased ﬁbrogenesis [17], the so-called “sclerodermic
penis”.Infact,theprevalenceofEDinmenwithSSchasbeen
reported as high as 80% [18] and it can be considered an
end-organ disease involving both macro and microvascular
damage.
2. Pathophysiology of Sclerodermic
ErectileDysfunction
Hormonal derangement is a common ﬁnding in SSc patients
even if a hormonal basis for impotence, that is, abnor-
malities in serum testosterone, follicle-stimulating hormone,
luteinizing hormone, prolactin, and oestradiol, has never
been demonstrated. Neurological causes could also be
excluded. In contrast, penile blood pressure, but not ankle
blood pressure indices, were found to be diminished [19].
DuplexsonographymeasurementsinmaleSScpatientsshow
impaired peak systolic velocities (PSVs) in penile arteries
and also the presence of veno-occlusive dysfunction. The
latter is often associated with the identiﬁcation of diﬀuse
hyperechogenic “spots” inside the corpora cavernosa, along
with a thickening of the tunica albuginea and is consistent
with the presence of a high degree of corporeal ﬁbrosis [20].
In a recent angiographic study it has been demonstrated
that the prevalence of coronary artery disease in SSc patients
is not diﬀerent from a control group [21]. In accordance,
our studies found that the intima-media-thickness (IMT)
of the common carotid artery of patients with ED in the
context of SSc is normal, thus conﬁrming that advanced
atherosclerosis occurs late in the course of disease. By
contrast, endothelial dysfunction is present early, as we were
able to demonstrate with impaired thermal recovery of the
penis after cold exposure [22]. Taken together, these data
indicate an altered arterial blood ﬂow in the absence of
general atherosclerosis as it is common in end-organ disease.
Indeed, an increased collagen synthesis by smooth muscle
cells and the accumulation of extracellular matrix had been
already demonstrated in patients with SSc [23], and it is
known that under hypoxic conditions of various origin,
transforming growth factor beta (TGFβ1), platelet-derived
growth factor (PDGF) and its receptors are overexpressed
in the corpora cavernosa [24]. TGFβ1a n dP D G Fh a v e
both been identiﬁed as important regulators of the collagen
and extracellular matrix synthesis by smooth muscle cells
and also act as smooth muscle mitogens. Under hypoxic
conditions, human penile smooth muscle cells also release
ET-1 and induce ET-B receptor expression, processes that
in turn are strongly increased by TGFβ1 and ET-1 itself
[25].Theseresultssuggestthatthemolecularmechanismsby
which penile hypoxia of any cause induce penile ﬁbrosis are
similar to those implicated in the ﬁbrotic transformation of
tissues in SSc patients [26]. The hypoxic and the SSc-speciﬁc
processes may thus contribute to, and even perpetuate, each
other in the manifestation of ED.International Journal of Rheumatology 3
Contradictory attitudes exist about the mechanisms of
the vasospastic arteriolar paroxysms—from hyperactivity of
the sympathetic nervous system and “local defect” with
receptor and nerve endings’ dysfunctions, endothelial dys-
regulation and blood cells’ activation to statements of pri-
mary central nervous mechanism. The venoarteriolar reﬂex
is a local mechanism protecting the capillary bed against
high hydrostatic pressure and therefore the tissue against
edema. The underlying mechanism of the venoarteriolar
reﬂex is still debated, although it is commonly believed
to depend on an intact innervations of the arterioles by
sympathetic vasoconstrictor ﬁbers [27]. The modulating
role of endothelium with its inﬂuence on the contractile
behaviour of precapillary resistance vessels is also assumed
so we can hypothesize that an autonomic nervous system
dysregulation can play an important role in determining
microvascular damage in sclerodermic patients. Evidence-
based studies aimed to investigate neurological involvement
in SSc patients are lacking.
3.DiagnosticApproach
The diagnosis of scleroderma is not always easy. If sclero-
derma is suspected, tests should be ordered to conﬁrm the
diagnosis, as well as to determine the severity of the disease.
Major body changes determined by SSc are often responsible
for increased morbidity and mortality, and may contribute
to the occurrence of psychological disturbances such as
anxiety and depression, whereas the incidence of psychotic
symptoms is very low in SSc patients [28]. It is known
that SSc patients are more vulnerable to depression [29],
and psychological interventions including counseling with
special psychotherapists and even antidepressant medication
may prevent the development of depression in such patients.
Further studies are needed to conﬁrm our ﬁndings in
a prospective manner if possible, and also to determine
whether depression is an important prognostic indicator for
quality of life in SSc. and an important breakthrough can
be made in understanding the underlying mechanisms of
psychiatric manifestations, in order to improve therapeutic
management and quality of life. Furthermore, an accurate
psychological assessment in SSc men with ED is recom-
mended.
ED should always be investigated with appropriate
questionnaires and dynamic penile Duplex ultrasound. In
fact,penilevasculardamageoccursinalmostallSScpatients,
regardless of clinical symptoms and we have suggested
that investigation of these patients with Duplex ultrasound
is mandatory for documenting the degree of vascular
involvement since the self-administered International Index
of Erectile Function questionnaire does not oftenmatch with
vascular ﬁndings [20]. In addition, we have demonstrated
that penile thermal proprieties of SSc patients diﬀer from
healthy controls, by using functional infrared imaging [22].
Data collected in this late pilot study demonstrate that
SSc patients’ penile temperature appears to be lower than
that of the healthy controls. In particular, it seems that
major diﬀerences are found at the level of the corpora,
while minor but still signiﬁcant diﬀerences are pointed out
for the temperature of the glans penis. Since cutaneous
temperature depends on cutaneous blood ﬂow and thermal
exchanges with deeper tissues (by convection through the
arterovenous network and by conduction from vessel walls
to tissues), the results seem to suggest the existence of
functional alterations of both tissue properties and blood
ﬂow. Penile temperature response to thermal stress seems to
conﬁrm such a hypothesis since SSc patients counteract to
and recover from cooling diﬀerently from controls. There-
fore, assessing whether thermal properties and temperature
controlprocessesofthepenisinSScpatientsarealteredcould
provide clues on potential ED, the progression of the illness
and the eﬀectiveness of possible treatments [22].
After careful review of clinical and instrumental data
already published in our previous papers, we suggest that
there is a relationship between ED and SSc vascular damage
evaluated by capillaroscopic pattern and vascular domain of
Medsger Disease Severity Scale (DSS) [30]. In our opinion
ED is present at onset in all patients with SSc, but early
stage of ED it can be attributed to a reduced penile
arterial inﬂow that is similar to RP of the hands and that
conﬁgures the “sclerodermic penis”. With the progression
of micromacrovascular damage in the natural course of
the disease, a concomitant penile ﬁbrosis and venocclusive
dysfunction occur leading to diﬃcult-to-treat ED.
For these reasons, a multidisciplinary approach to SSc
patients would involve the rheumatologist, the uro/androl-
ogist and the psychiatrist to comprehensively evaluate all
diagnostic aspects.
4. Treatment
The treatment of ED in SSc suggest to modify or revert risk
factors for ED, including lifestyle, psychological or drug-
related factors, but such treatments are often unsatisfactory
and limited by frequent side eﬀects in the long-term. Three
diﬀerent phosphodiesterase type-5 (PDE5) inhibitors are
currentlyavailable:sildenaﬁl,vardenaﬁlandtadalaﬁl.Several
randomized trials have demonstrated the eﬃcacy of this
class of medications, but there are no compelling data to
support the superiority of one PDE5 inhibitor over another
in non-SSc patients. The three PDE5 inhibitors share many
pharmacological and clinical characteristics. Initial studies
involvinganimalmodels,datafromopen-label,uncontrolled
trials involving patients with pulmonary arterial hyperten-
sion, and a small randomized, controlled studies involving
patients with idiopathic pulmonary arterial hypertension
suggest that PDE5 inhibitors are beneﬁcial in the treatment
of pulmonary arterial hypertension [31–33]. Recently some
authors have shown that sildenaﬁl may be complimentary
in the treatment of RP refractory to conventional drugs
[34, 35]. Several studies have corroborated the eﬃcacy of
PDE5 inhibitors in the treatment of ED related to several
internistic disease such as atherosclerosis, mellitus diabetes,
arterial hypertension [36]. This improvement is conﬁrmed
alsobysexualquestionnairesandsuggestsPDE5inhibitorsas
an adjunctive therapy that might possibly reverse the process4 International Journal of Rheumatology
of endothelial damage leading to vascular disease in SSc.
In a recent study, we demonstrated that once-daily tadalaﬁl
is able to decrease the mean number of Raynaud’s attacks
by reducing surrogate markers of vascular damage such as
adrenomedullin and ET-1 plasma levels. The results of that
study lead us to postulate the beneﬁcial eﬀect of adding daily
long-term PDE5 inhibitors to the medical treatment of SSc
[37]. The use of endothelin-receptor antagonists (ERAs) in
SSc is actually deserved to patients with severe pulmonary
arterial hypertension. The possibility of an add-on eﬀect of
ERAs to PDE5i is to be considered in future studies. At the
moment, no proof-of-fact that the use of ERAs alone may
i m p r o v eE Di sp r e s e n t .
In the era of PDE5 inhibitors, we believe that the
implantation of a penile prosthesis may be considered only
in patients who fail pharmacotherapy or who prefer a per-
manent solution of their problem. The choice of prosthesis is
depends from patients’ preference and his manual dexterity.
This solution may have an high satisfaction rate as in the
non-SSc population but must take into account that it is not
reversible. Finally, mechanical failures and infection has the
same occurrence (1%–3%) than the general population [38].
5. Conclusion
Long-standing SSc is almost always associated with the
presence of some degree of ED, because of micro and
macrovascular disseminated damage through cavernosal
penile arteries and capillaries and subsequent cavernosal
ﬁbrosis. As a consequence, ED should be systematically
questionedandcounselledinanypatientpresentingwithSSc
by a specialized team. Although robust data on treatment
options for ED in the SSc population are not yet available,
empirical treatment should be started with a daily or
alternatedayregimenofalong-actingPDE5iafteraddressing
modiﬁable risk factors for ED. Second-line treatment deci-
sions require the cooperation between expert specialists in
order to maximize medical therapy beneﬁts for underlying
conditions.
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